CAR T-cell therapy improves survival in relapsed or refractory lymphoma

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone lymphoma, according to a recent clinical trial published in The Lancet. Marginal zone lymphoma (MZL) is a group of rare and slow-growing non-Hodgkin ly...

🔗 Read more: https://medicalxpress.com/news/2026-03-car-cell-therapy-survival-relapsed.html

#News #Medicine #Health #Policy #Biology #Science